The Review Of
DIABETIC
STUDIES OPEN ACCESS

Recent Advances In Antidiabetic Phytochemicals: Bridging Traditional Remedies And Next-Generation Therapeutics

Mithul V Mammen[1], Abhishek Suman[2], Amit Kumar[2], Dimple Pratap Singh[2], Abhishek Anand[1], Shagufta Parveen[1]

[1]Department of Pharmacy Practice, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India -244001
[2]Shri Venkateshwara School of Pharmacy, Shri Venkateshwara University, Rajabpur, Gajraula, Amroha, Uttar Pradesh, India
Corresponding author:
*Name & Address of Corresponding – Amit Kumar**
E-mail ID:amittph1812017@gmail.com
Shri Venkateshwara School of Pharmacy, Shri Venkateshwara University, Rajabpur, Gajraula, Amroha, Uttar Pradesh, India

ABSTRACT

Diabetes mellitus (DM) is one of the most pressing global health concerns of the 21st century, characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The limitations of existing pharmacological therapies, such as side effects, drug resistance, and high costs, have intensified the search for alternative and adjunctive therapeutic options. Phytochemicals—bioactive plant-derived compounds—have long been utilized in traditional medicine systems and are increasingly gaining attention as promising antidiabetic agents. These compounds, including flavonoids, alkaloids, terpenoids, and polyphenols, exert multifaceted antidiabetic effects, such as enhancing insulin sensitivity, promoting pancreatic β-cell regeneration, modulating glucose transport, inhibiting carbohydrate-digesting enzymes, and regulating oxidative stress and inflammation.

Recent advances in phytochemistry, nanotechnology, molecular docking, and pharmacogenomics have deepened our understanding of these compounds, bridging traditional remedies with next-generation therapeutic approaches. Several phytochemicals, such as berberine, curcumin, resveratrol, quercetin, and ginsenosides, have progressed from bench research to preclinical and clinical evaluation, demonstrating favorable outcomes in glycemic control and metabolic regulation. Nevertheless, challenges persist, including poor bioavailability, variability in plant-derived preparations, safety concerns, and regulatory barriers.

This review aims to provide a comprehensive update on recent advances in antidiabetic phytochemicals, critically analyzing their mechanisms of action, translational potential, and clinical applications. It also highlights innovations in drug delivery systems, synergistic combinations with conventional antidiabetic drugs, and the integration of artificial intelligence in phytochemical discovery. By bridging ethnopharmacological knowledge with modern drug development, phytochemicals may play a pivotal role in shaping future personalized therapies for diabetes management.

INTRODUCTION

Diabetes mellitus (DM) represents one of the most significant and rapidly growing health challenges worldwide. The condition is a chronic metabolic disorder characterized by persistent hyperglycemia due to defects in insulin secretion, insulin action, or both. It is broadly classified into type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), gestational diabetes mellitus (GDM), and other specific types caused by genetic or secondary factors [1]. Among these, T2DM constitutes more than

90% of all diabetes cases and is strongly associated with obesity, sedentary lifestyles, and genetic predisposition [2].

The International Diabetes Federation (IDF) has projected that the global prevalence of diabetes will increase from 537 million adults in 2021 to 783 million by 2045, placing a tremendous burden on healthcare systems and economies [3]. Diabetes is also a major risk factor for cardiovascular disease, chronic kidney disease, neuropathy, retinopathy, and lower-limb amputations, collectively contributing to increased morbidity and mortality [4].

Limitations of Conventional Antidiabetic Therapies

Over the last few decades, the development of pharmacological agents such as biguanides (e.g., metformin), sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose co-transporter-2 inhibitors has significantly advanced diabetes management [5,6]. However, these agents are not without limitations. Issues such as hypoglycemia, gastrointestinal disturbances, cardiovascular risks, weight gain, and high treatment costs limit their long-term applicability [7,8]. Moreover, progressive decline in β-cell function in T2DM patients often necessitates the use of combination therapy or insulin, further complicating treatment regimens [9].

The Role of Traditional Medicine and Phytochemicals

In light of these challenges, interest in alternative and complementary therapeutic approaches has intensified. Traditional medicine systems such as Ayurveda, Traditional Chinese Medicine (TCM), and African ethnomedicine have long employed plant-based remedies for the management of diabetes [10,11]. For instance, Momordica charantia (bitter melon), Trigonella foenum-graecum (fenugreek), Gymnema sylvestre, and Panax ginseng have been widely recognized for their hypoglycemic potential [12–14]. Traditional medicine systems such as Ayurveda, Traditional Chinese Medicine (TCM), and Kampo have long utilized plants for diabetes treatment. Recent advances in phytochemistry, molecular pharmacology, and bioinformatics have helped validate many of these remedies [16]. Phytochemicals—naturally occurring bioactive compounds in plants—are believed to be the active constituents responsible for these effects. These include alkaloids, flavonoids, terpenoids, saponins, and phenolic acids, which exhibit diverse pharmacological activities such as insulin sensitization, modulation of glucose metabolism, inhibition of carbohydrate-digesting enzymes, and antioxidant/anti-inflammatory effects [15–17]. Unlike synthetic drugs that often target a single pathway, phytochemicals frequently act on multiple molecular targets, offering a holistic therapeutic approach [18]. Classes of phytochemicals with antidiabetic properties include alkaloids, flavonoids, terpenoids, saponins, and phenolic acids (Table 1).

Table 1. Major classes of antidiabetic phytochemicals and their representative compounds

Phytochemical Class	Representative Compounds	Plant Sources	Primary Mechanism(s) of Action
Alkaloids	Berberine	Berberis aristata	AMPK activation, inhibition of gluconeogenesis
Flavonoids	Quercetin, Kaempferol	Onions, tea, apples	GLUT4 translocation, antioxidant effects
Polyphenols	Resveratrol	Grapes, berries, peanuts	SIRT1 activation, mitochondrial function
Terpenoids	Ginsenosides	Panax ginseng	PI3K/Akt activation, insulin secretion
Xanthones	Mangiferin	Mango leaves	AMPK activation, antioxidant protection
Phenolic acids	Chlorogenic acid	Coffee	Inhibition of α-glucosidase, reduced glucose absorption

Recent Advances in Phytochemical Research

In the last two decades, there has been a surge of research exploring the antidiabetic potential of phytochemicals. Advances in phytochemistry, molecular biology, nanotechnology, and bioinformatics have enabled the identification of active compounds, their mechanisms of action, and their therapeutic relevance [19,20].

Current drugs such as metformin, sulfonylureas, GLP-1 agonists, and SGLT2 inhibitors target isolated aspects of these mechanisms but do not fully address the multi-factorial nature of T2DM. Moreover, progressive β-cell dysfunction often leads to therapy failure [20].

Phytochemicals offer a multi-target approach, modulating oxidative stress, inflammation, insulin sensitivity, and β-cell regeneration simultaneously, thereby addressing the complexity of diabetes pathophysiology [21].

Table 2. Key mechanisms in T2DM pathophysiology and limitations of current therapies

Pathogenic Mechanism	Conventional Drug Targets	Limitations of Current Drugs	Phytochemical Potential
Insulin resistance	Metformin, TZDs	GI side effects, weight gain	AMPK activation by berberine, resveratrol
β-cell dysfunction	Sulfonylureas, GLP-1 agonists	Loss of efficacy, hypoglycemia	Pancreatic protection by quercetin, ginsenosides
Excess gluconeogenesis	Metformin	Incomplete suppression	Curcumin, mangiferin
Lipotoxicity	GLP-1 agonists	Limited action on lipid metabolism	Flavonoids (reduce adipose inflammation)
Oxidative stress	Indirect via metformin	Partial benefit	Polyphenols (resveratrol, catechins)
Inflammation	None directly	No specific drug	Curcumin, quercetin suppress NF-κB
Gut microbiota	Not directly targeted	Variable effects	Berberine, resveratrol modulate microbiome

Compounds such as berberine, resveratrol, curcumin, quercetin, and ginsenosides have attracted considerable attention for their multifaceted effects on glucose regulation and insulin signaling [21–23]. Some of these compounds have entered clinical trials, showing efficacy comparable to standard oral antidiabetic drugs [24].

Moreover, novel approaches such as nanoparticle-based delivery systems and structural modification of phytochemicals are being developed to overcome pharmacokinetic limitations like poor solubility and low bioavailability [25]. Computational tools, including molecular docking and network pharmacology, have further accelerated the discovery and optimization of plant-derived compounds [26].

Bridging Traditional Remedies and Next-Generation Therapeutics

The integration of ethnopharmacological wisdom with modern drug discovery frameworks is a promising avenue in diabetes research. While traditional remedies provide a foundation for identifying effective plant species, modern analytical tools validate their efficacy, elucidate mechanisms, and enhance clinical translation [27]. Bridging these two domains is crucial for developing standardized, safe, and effective phytochemical-based therapeutics.

This review aims to critically examine recent advances in antidiabetic phytochemicals, with particular focus on their mechanisms of action, translational research, preclinical and clinical studies, and innovations in drug delivery systems. It will also discuss challenges such as variability in plant extracts, regulatory hurdles, and safety concerns, while highlighting opportunities for future personalized diabetes care through phytochemical therapeutics.

Overview of Phytochemicals in Antidiabetic Therapy

Phytochemicals are bioactive compounds naturally occurring in plants, many of which exert significant pharmacological actions. For centuries, plant-based remedies have served as primary therapeutic agents for managing diabetes across traditional medical systems, including Ayurveda, Traditional Chinese Medicine (TCM), and African ethnopharmacology [28,29]. With modern analytical and pharmacological tools, numerous phytochemicals have been isolated, structurally characterized, and evaluated for antidiabetic effects, revealing promising potential for drug development [30,31].

Classification of Antidiabetic Phytochemicals

Phytochemicals with hypoglycemic properties are broadly classified into several categories: alkaloids, flavonoids, terpenoids, phenolic compounds, glycosides, and saponins. These groups differ in chemical structure and biological activities but converge in their ability to modulate glucose homeostasis [32].

- Alkaloids: These nitrogen-containing compounds, such as berberine and trigonelline, improve insulin sensitivity, inhibit α-glucosidase, and modulate gut microbiota [33,34].
- Flavonoids: A large class of polyphenolic compounds (e.g., quercetin, kaempferol, epigallocatechin gallate) with antioxidant, anti-inflammatory, and insulin-sensitizing effects [35].
- Terpenoids: Compounds like ginsenosides and gymnemic acids modulate glucose uptake and insulin secretion [36].
- Phenolic acids: Chlorogenic acid and caffeic acid influence glucose absorption and hepatic gluconeogenesis [37].
- Saponins: These glycosides, including diosgenin, exhibit insulin-mimetic activity and improve lipid metabolism [38].
- Other bioactive compounds: Stilbenes (resveratrol), curcuminoids (curcumin), and xanthones (mangiferin) also demonstrate multifaceted antidiabetic effects [39,40].

Class	Representative Compounds	Plant Sources	Principal Mechanisms
Alkaloids	Berberine	Berberis aristata, Coptis chinensis	AMPK activation, inhibition of gluconeogenesis
Flavonoids	Quercetin, Kaempferol, Naringenin	Onions, citrus fruits, tea	GLUT4 translocation, antioxidant activity
Terpenoids	Ginsenosides (Rg1, Rb1, Re)	Panax ginseng	PI3K/Akt activation, β-cell protection
Polyphenols (Stilbenes)	Resveratrol	Grapes, peanuts, berries	SIRT1 activation, mitochondrial biogenesis
Xanthones	Mangiferin	Mango leaves,	AMPK activation, oxidative stress reduction

		Swertia chirayita	
Phenolic acids	Chlorogenic acid, Caffeic acid	Coffee, apples	α-glucosidase inhibition, reduced glucose absorption
Saponins	Gymnemic acids	Gymnema sylvestre	Glucose absorption inhibition, insulin secretion enhancement

Ethnopharmacological Roots

Ethnopharmacological knowledge has been a cornerstone for the identification of antidiabetic plants and their phytoconstituents. Plants like Momordica charantia (bitter melon), Trigonella foenum-graecum (fenugreek), Gymnema sylvestre, and Ocimum sanctum have been used traditionally for diabetes management and later validated in pharmacological studies [41,42]. This traditional foundation highlights the importance of systematic documentation and modern validation of indigenous knowledge.

Mechanistic Diversity

Phytochemicals exert antidiabetic effects through a broad spectrum of mechanisms:

- Insulin sensitization: Flavonoids such as quercetin activate AMP-activated protein kinase (AMPK), enhancing glucose uptake [43].
- Stimulation of insulin secretion: Alkaloids like trigonelline and terpenoids like ginsenosides promote pancreatic β-cell function [44,45].
- Inhibition of carbohydrate-digesting enzymes: Compounds like berberine and chlorogenic acid inhibit α-amylase and α-glucosidase, reducing postprandial hyperglycemia [46].
- Antioxidant and anti-inflammatory activity: Polyphenols scavenge free radicals and modulate inflammatory pathways that contribute to insulin resistance [47].
- Modulation of gut microbiota: Certain alkaloids and saponins improve gut microbial composition, indirectly regulating glucose metabolism [48].
- Protection of pancreatic β-cells: Flavonoids and curcuminoids reduce oxidative stress–induced apoptosis in pancreatic cells [49].

Synergistic and Polyherbal Formulations

Unlike conventional drugs, which usually target single pathways, phytochemicals often act on multiple molecular targets. This multi-target action makes them ideal candidates for combination therapies or polyherbal formulations [50]. For instance, formulations containing Gymnema sylvestre and Momordica charantia exhibit synergistic effects, enhancing glycemic control beyond individual constituents [51]. However, standardization of such formulations remains a challenge.

Preclinical and Clinical Relevance

Numerous preclinical studies support the antidiabetic effects of phytochemicals, with several compounds progressing to clinical trials. Berberine, for example, has been shown to reduce fasting blood glucose and HbA1c levels in patients with T2DM, with efficacy comparable to metformin [52]. Similarly, resveratrol and curcumin have demonstrated improvements in insulin sensitivity and lipid metabolism in human studies [53,54]. These findings underscore the translational potential of phytochemicals in diabetes management.

Challenges in Phytochemical Research

Despite their promise, several challenges limit the clinical application of phytochemicals. These include variability in plant sources, seasonal changes in phytochemical content, poor bioavailability, and lack of standardized extraction and dosing protocols [55]. Moreover, herb–drug interactions and long-term safety profiles require further investigation [56]. Addressing these limitations through modern drug delivery systems, nanotechnology, and rigorous clinical trials will be essential for their successful integration into mainstream therapeutics.

Molecular Mechanisms of Antidiabetic Phytochemicals

Phytochemicals exert antidiabetic effects through diverse biochemical and molecular pathways that target the key pathophysiological mechanisms of diabetes mellitus (DM). Unlike single-target synthetic drugs, phytochemicals often display pleiotropic activities, acting simultaneously on multiple molecular pathways [57]. This section provides an in-depth overview of the principal mechanisms, supported by evidence from in vitro, in vivo, and clinical studies.

Enhancement of Insulin Secretion and Pancreatic β-Cell Function

Pancreatic β-cell dysfunction is central to both type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). Several phytochemicals have been shown to stimulate insulin secretion or protect β-cells from apoptosis.

- Alkaloids: Berberine enhances insulin secretion via activation of phosphoinositide 3-kinase (PI3K)/Akt and modulation of AMP-activated protein kinase (AMPK) signaling [58]. Trigonelline, found in fenugreek seeds, improves β-cell regeneration by upregulating pancreatic transcription factors like Pdx-1 [59].
- Flavonoids: Quercetin and genistein directly stimulate insulin secretion in pancreatic islets by modulating calcium signaling and cyclic adenosine monophosphate (cAMP) pathways [60,61].
- Terpenoids: Ginsenosides (Rg1, Rb1) enhance insulin release by increasing GLUT2 expression in β-cells and protecting against glucotoxicity [62].

Animal studies confirm that phytochemicals not only enhance insulin release but also preserve β-cell architecture under diabetic stress conditions [63]

Improvement of Insulin Sensitivity

Peripheral insulin resistance in skeletal muscle, liver, and adipose tissue is a hallmark of T2DM. Phytochemicals improve insulin sensitivity through modulation of glucose transporters and signaling cascades.

- AMPK activation: Polyphenols such as resveratrol and epigallocatechin gallate (EGCG) activate AMPK, promoting glucose uptake in skeletal muscle [64].
- PPARγ modulation: Diosgenin and curcumin act as peroxisome proliferator-activated receptor gamma (PPARγ) agonists, enhancing adipocyte insulin sensitivity [65,66].
- GLUT4 translocation: Flavonoids like kaempferol increase insulin-stimulated GLUT4 translocation in adipocytes [67].

These molecular effects mirror those of thiazolidinediones (synthetic PPARγ agonists), but with potentially fewer adverse effects [68].

Inhibition of Carbohydrate-Digesting Enzymes

Controlling postprandial hyperglycemia is crucial in diabetes management. Several phytochemicals inhibit intestinal enzymes responsible for carbohydrate digestion and absorption.

- α-Amylase and α-Glucosidase inhibition: Berberine, chlorogenic acid, and gymnemic acids inhibit these enzymes, reducing glucose absorption [69,70].
- Sucrase and maltase inhibition: Flavonoids such as luteolin and apigenin selectively suppress disaccharidase activity in intestinal mucosa [71].

These actions mimic the pharmacological effects of acarbose, though phytochemicals may have improved tolerability [72].

Antioxidant Defense and Reduction of Oxidative Stress

Oxidative stress plays a critical role in β-cell dysfunction and insulin resistance. Many phytochemicals exhibit potent antioxidant activity by scavenging reactive oxygen species (ROS) and enhancing endogenous antioxidant defenses.

- Direct free radical scavenging: Curcumin and resveratrol neutralize ROS and reactive nitrogen species [73].
- Nrf2 pathway activation: Polyphenols activate nuclear factor erythroid 2–related factor 2 (Nrf2), upregulating antioxidant enzymes such as superoxide dismutase (SOD) and glutathione peroxidase (GPx) [74].
- Mitochondrial protection: Flavonoids like catechins improve mitochondrial integrity, preventing oxidative damage–induced apoptosis [75].

Clinical trials have confirmed reductions in oxidative stress biomarkers after supplementation with resveratrol and curcumin in diabetic patients [76,77].

Anti-Inflammatory Effects

Chronic low-grade inflammation contributes to insulin resistance. Several phytochemicals modulate inflammatory pathways:

- NF-κB inhibition: Curcumin, quercetin, and berberine suppress NF-κB signaling, reducing cytokine production (TNF-α, IL-6) [78].
- Cytokine modulation: Resveratrol reduces circulating pro-inflammatory cytokines while increasing adiponectin [79].
- JNK and MAPK inhibition: Terpenoids such as ginsenosides inhibit stress-activated protein kinases that impair insulin signaling [80].

These findings highlight phytochemicals as natural anti-inflammatory agents with metabolic benefits.

Modulation of Gut Microbiota

Gut microbiota dysbiosis has emerged as a key factor in T2DM pathophysiology. Phytochemicals interact with gut microbiota, enhancing metabolic health.

- Prebiotic effects: Saponins and polyphenols act as substrates for beneficial bacteria such as Bifidobacterium and Lactobacillus [81].
- Berberine–microbiota interaction: Berberine alters gut microbial composition, increasing short-chain fatty acid (SCFA)-producing bacteria, thereby improving insulin sensitivity [82].

- Flavonoid metabolism: Gut microbiota metabolizes flavonoids into bioactive metabolites with improved bioavailability [83].

These bidirectional interactions suggest that phytochemical efficacy may depend on an individual's gut microbial composition [84].

Protection Against Advanced Glycation End Products (AGEs)

Hyperglycemia accelerates the formation of AGEs, which damage tissues and exacerbate diabetic complications.

- AGE formation inhibition: Phenolic compounds such as caffeic acid and ferulic acid inhibit glycation reactions [85].
- AGE receptor modulation: Resveratrol downregulates receptor for AGEs (RAGE) expression, reducing vascular complications [86].

Such mechanisms may contribute to phytochemicals' protective role in diabetic nephropathy and retinopathy.

Epigenetic and Genomic Modulation

Emerging evidence suggests phytochemicals influence epigenetic regulation of metabolic genes.

- DNA methylation: Curcumin demethylates PPARγ promoter regions, enhancing insulin sensitivity [87].
- Histone modifications: Resveratrol modulates histone acetylation through sirtuin activation, regulating glucose metabolism genes [88].
- MicroRNA regulation: Quercetin modulates microRNAs involved in insulin signaling, such as miR-29 and miR-122 [89].

Figure: Mechanisms of Action of Antidiabetic Phytochemical



Specific Phytochemicals with Antidiabetic Potential

Several individual phytochemicals have been extensively studied for their potential in diabetes therapy. These compounds, derived from medicinal plants, exhibit diverse pharmacological actions ranging from insulin sensitization to anti-inflammatory effects. This section discusses key antidiabetic phytochemicals, emphasizing their sources, mechanisms, and translational potential.

Berberine

Berberine, an isoquinoline alkaloid derived from Berberis species, is one of the most widely investigated phytochemicals in diabetes research.

- Mechanisms: Berberine activates AMPK, enhances glucose uptake, reduces gluconeogenesis, and modulates gut microbiota [90,91]. It also inhibits α-glucosidase and improves insulin receptor expression [92].
- Clinical evidence: Randomized controlled trials (RCTs) show that berberine reduces fasting plasma glucose (FPG), HbA1c, and lipid levels, with efficacy comparable to metformin [93].
- Limitations: Poor bioavailability and gastrointestinal side effects remain barriers to clinical adoption [94]. Novel formulations, including nanoparticles and liposomes, are being developed to improve pharmacokinetics [95].

Curcumin

Curcumin, the principal polyphenolic compound in turmeric (Curcuma longa), has been shown to modulate multiple diabetes-related pathways.

- Mechanisms: Curcumin improves insulin sensitivity by activating PPARγ and AMPK pathways, suppresses NF-κB–mediated inflammation, and enhances antioxidant defenses [96].
- Clinical evidence: A landmark RCT demonstrated that curcumin supplementation delayed the onset of T2DM in prediabetic individuals [97]. Additional trials confirm reductions in FPG, HbA1c, and inflammatory markers [98].
- Limitations: Curcumin suffers from low bioavailability due to poor absorption and rapid metabolism. Piperine co-administration or nanoparticle formulations improve its systemic availability [99].

Resveratrol

Resveratrol, a stilbene found in grapes, peanuts, and berries, has gained attention for its metabolic and cardioprotective benefits.

- Mechanisms: Resveratrol activates SIRT1 and AMPK, improves mitochondrial function, and reduces oxidative stress [100]. It also modulates gut microbiota composition [101].
- Clinical evidence: Meta-analyses of RCTs suggest resveratrol supplementation improves insulin sensitivity, lowers FPG, and reduces inflammatory biomarkers in T2DM patients [102,103].
- Limitations: Inter-individual variability in response and short half-life limit its clinical utility [104].

Quercetin

Quercetin, a flavonoid abundant in onions, apples, and tea, exhibits strong antioxidant and anti-inflammatory properties.

- Mechanisms: Quercetin enhances GLUT4 translocation, activates AMPK, and suppresses pro-inflammatory cytokines [105]. It also protects pancreatic β-cells from oxidative stress [106].
- Clinical evidence: Human studies indicate modest reductions in blood glucose and improvements in lipid profile with quercetin supplementation [107].
- Limitations: Variable results in clinical trials suggest that dosage, formulation, and individual metabolic profiles influence efficacy [108].

Ginsenosides

Ginsenosides, the active saponins in Panax ginseng, have been traditionally used in Asian medicine for metabolic disorders.

- Mechanisms: Ginsenosides enhance insulin secretion, improve glucose uptake, and modulate inflammatory Apathways [109]. Specific ginsenosides (Rg1, Rb1, Re) activate PI3K/Akt and AMPK signaling [110].
- Clinical evidence: RCTs demonstrate that ginseng supplementation improves glycemic control and insulin sensitivity in patients with impaired glucose tolerance [111].
- Limitations: Variability in ginsenoside content among preparations complicates standardization [112].

Mangiferin

Mangiferin, a xanthone glucoside found in mango leaves and Swertia chirayita, is an emerging antidiabetic phytochemical.

- Mechanisms: It improves glucose metabolism by activating AMPK, reducing oxidative stress, and inhibiting α-glucosidase [113].
- Preclinical evidence: Animal studies show significant reductions in blood glucose and improvements in insulin sensitivity [114].
- Clinical potential: Few clinical trials exist, but early findings suggest promise as an adjunct therapy [115].

Other Promising Compounds

- Catechins (EGCG): Found in green tea, EGCG improves glucose uptake and reduces inflammation [116].
- Chlorogenic acid: Present in coffee, it lowers postprandial glucose by inhibiting carbohydrate digestion [117].
- Gymnemic acids (Gymnema sylvestre): Suppress intestinal glucose absorption and enhance insulin secretion [118].

Safety Profiles of Key Antidiabetic Phytochemicals

Berberine

Berberine is generally well-tolerated but is associated with gastrointestinal side effects such as diarrhea, constipation, and abdominal discomfort [122]. At high doses, it may interfere with cytochrome P450 enzymes, leading to drug–drug interactions, particularly with statins, oral hypoglycemics, and anticoagulants [123].

Curcumin

Curcumin has a wide safety margin, with studies reporting tolerability up to 8 g/day without significant toxicity [124]. However, its poor bioavailability raises concerns regarding the use of nanoparticle and liposomal formulations, as long-term safety data on these delivery systems remain limited [125].

Resveratrol

Resveratrol supplementation is generally safe up to 1 g/day, though higher doses may cause gastrointestinal upset and headache [126]. Importantly, it can interact with anticoagulants such as warfarin due to its antiplatelet activity [127].

Quercetin

Quercetin is considered safe at dietary intake levels but may exhibit nephrotoxicity at high doses in animal models [128]. Limited human studies exist on its long-term safety, necessitating caution in recommending supplemental forms beyond typical dietary levels [129].

Ginsenosides

Ginseng extracts are widely consumed, but adverse effects such as insomnia, hypertension, and gastrointestinal symptoms have been reported at high doses [130]. Case reports describe rare hepatotoxicity and interactions with hypoglycemic agents leading to hypoglycemia [131].

Herb–Drug Interactions

One of the major concerns in phytotherapy is the potential for herb–drug interactions. Many phytochemicals modulate drug-metabolizing enzymes (CYP450 family) and drug transporters (P-glycoprotein), which can alter the pharmacokinetics of conventional drugs [132]. For example:

- Berberine inhibits CYP2D6 and CYP3A4, affecting metabolism of metformin and statins [123].
- Curcumin inhibits CYP2C9 and CYP3A4, potentially interacting with sulfonylureas and warfarin [125].
- Resveratrol interferes with CYP2C9, impacting anticoagulants and some antidiabetic drugs [127].
- Ginseng may potentiate insulin and oral hypoglycemics, leading to additive hypoglycemic effects [131].

Table 7. Common phytochemicals and potential drug interactions

Phytochemical	Interacting Drugs	Mechanism	Clinical Concern
Berberine	Metformin, statins, warfarin	CYP2D6/CYP3A4 inhibition	Drug accumulation, enhanced effects
Curcumin	Sulfonylureas, warfarin	CYP2C9 inhibition	Hypoglycemia, bleeding risk
Resveratrol	Warfarin, NSAIDs	Antiplatelet effect, CYP2C9 inhibition	Bleeding complications
Quercetin	Cyclosporine, cisplatin	Renal metabolism interference	Nephrotoxicity risk
Ginsenosides	Insulin, sulfonylureas	Additive hypoglycemia	Hypoglycemia episodes

Toxicological Evidence

Preclinical toxicology studies indicate that most phytochemicals have high LD50 values and wide safety margins [133]. However, concerns arise with chronic exposure and concentrated extracts:

- Berberine → hepatotoxicity at very high doses in rodents [134].
- Quercetin → DNA damage in some in vitro studies at supraphysiological concentrations [135].
- Resveratrol → mild nephrotoxicity reported in animal models at doses >1 g/kg [136].

Figure 14. Dose–response and safety margin curve of major antidiabetic phytochemicals → shows therapeutic vs. toxic dose ranges of berberine, curcumin, resveratrol, quercetin, and ginsenosides.

Regulatory Considerations

Regulation of phytochemicals varies significantly across regions:

- United States – Classified as dietary supplements under the Dietary Supplement Health and Education Act (DSHEA). Manufacturers are responsible for safety, but products are not strictly regulated like pharmaceuticals [137].
- European Union – Herbal products are regulated under the Traditional Herbal Medicinal Products Directive (THMPD), which requires quality, safety, and efficacy documentation [138].
- Asia (India, China, Japan) – Systems such as Ayurveda, TCM, and Kampo integrate phytochemicals into healthcare. India's AYUSH and China's State Food and Drug Administration (SFDA) regulate herbal medicines, though harmonization with Western standards remains incomplete [139].

The lack of global harmonization leads to variability in product quality, dosing, and labeling. Standardization of active constituents, toxicological testing, and pharmacovigilance remain urgent needs [140].

Strategies for Ensuring Safe Use

To optimize the clinical use of phytochemicals:

1. Standardization – Establishing consistent levels of active compounds (e.g., berberine content in extracts).
2. Pharmacovigilance – Implementing reporting systems for adverse events similar to conventional drugs.
3. Toxicological Testing – Conducting long-term studies for concentrated extracts and novel formulations (e.g., nanoparticles).
4. Regulatory Harmonization – Developing unified global guidelines for phytomedicine approval [141].

Future Perspectives

Emerging approaches such as nanotechnology-based formulations and AI-driven drug safety prediction can enhance phytochemical safety and reduce toxicity risks [142]. For example, nano-encapsulation of curcumin not only improves bioavailability but also minimizes systemic exposure, reducing off-target effects [143]. Machine learning models are increasingly applied to predict herb–drug interactions before clinical testing [144].

Future Directions and Next-Generation Therapeutics

The growing recognition of phytochemicals as multifunctional agents for diabetes management has catalyzed research into their translation into next-generation therapeutics. However, despite promising preclinical and clinical evidence, significant challenges remain regarding bioavailability, standardization, clinical trial design, regulatory harmonization, and integration with modern drug discovery tools [145]. Future strategies aim to combine traditional wisdom with cutting-edge technologies, thereby bridging the gap between natural compounds and precision medicine in diabetes care.

Addressing Bioavailability and Pharmacokinetics

One of the foremost challenges in phytochemical therapeutics is poor bioavailability. Many compounds such as curcumin, resveratrol, and quercetin exhibit low aqueous solubility, rapid metabolism, and limited systemic distribution [146].

Emerging strategies include:

- Nanoformulations – Nanoparticles, liposomes, and polymeric micelles improve solubility, stability, and controlled release [147].
- Phytosome technology – Complexing phytochemicals with phospholipids enhances absorption, as demonstrated for curcumin and quercetin [148].
- Prodrug approaches – Chemical modifications that increase intestinal permeability and reduce first-pass metabolism [149].
- Co-administration with bioenhancers – Piperine has been shown to increase curcumin bioavailability by 2000% in humans [150].



Figure : Nano-formulation Strategies for Phytochemicals

Integration of Multi-Omics and Systems Biology

Phytochemicals act on multiple molecular targets simultaneously, making them ideal candidates for network pharmacology approaches [151]. Integration of genomics, transcriptomics, metabolomics, and microbiomics allows for mapping the complex interactions between phytochemicals and host biology.

- Metabolomics identifies biomarkers of phytochemical response (e.g., resveratrol-induced changes in lipid metabolites).
- Microbiomics reveals gut microbiota modulation (e.g., berberine increases SCFA-producing bacteria, improving insulin sensitivity) [152].
- Network pharmacology models predict synergistic actions of compound combinations and identify key signaling hubs targeted by multiple phytochemicals [153].

Artificial Intelligence and Machine Learning in Phytochemical Discovery

AI-driven platforms are transforming natural product research. Machine learning models trained on structural and pharmacological databases can predict antidiabetic activity, toxicity, and drug–drug interactions of novel phytochemicals [154].

Applications include:

- In silico screening of large phytochemical libraries for AMPK or PPARγ activators.
- Predictive modeling of bioavailability and toxicity profiles.
- Drug repurposing – rediscovering known phytochemicals for new diabetes-related pathways.

Table 8. Role of AI in advancing phytochemical therapeutics

AI Application	Example	Impact
Virtual screening	Docking phytochemicals to AMPK/SIRT1	Identifies novel bioactives
Toxicity prediction	QSAR models for hepatotoxicity	Improves safety assessment
Synergy mapping	Network pharmacology with machine learning	Guides multi-compound formulations
Drug repurposing	Re-analysis of flavonoids	Expands therapeutic scope

Personalized and Precision Phytotherapy

The heterogeneity of diabetes underscores the need for personalized medicine. Phytochemicals could be integrated into precision nutrition strategies based on patient-specific genetic, metabolic, and microbiome profiles [155].

Examples:

- Genotype-specific responses: Certain PPARγ polymorphisms modulate patient responsiveness to resveratrol.
- Microbiome-driven effects: The antidiabetic efficacy of berberine is enhanced in individuals with higher baseline abundance of Akkermansia muciniphila [156].
- Nutrigenomics: Quercetin influences expression of glucose transporters depending on individual genetic variants [157].

Future clinical trials should adopt stratified designs, grouping participants by genetic or microbiome profiles to assess phytochemical responsiveness.

SYNERGISTIC COMBINATIONS AND POLYHERBAL FORMULATIONS

Traditional medicine often employs polyherbal formulations, which may act synergistically on multiple targets. Modern approaches are beginning to validate these practices using systems pharmacology and clinical testing [158].

Examples include:

- Berberine + Metformin → synergistic glucose-lowering effects with reduced metformin dose requirement [159].
- Curcumin + Piperine → enhanced curcumin bioavailability [150].
- Ginseng + Quercetin → combined antioxidative and insulin-sensitizing actions [160].

Figure 17. Synergistic actions of phytochemicals and conventional drugs in diabetes management → showing overlap in pathways like AMPK, NF-κB, PI3K/Akt.

REGULATORY INNOVATIONS FOR PHYTOCHEMICAL THERAPEUTICS

To ensure safe translation, regulatory bodies must adapt to phytochemical-based therapies:

- Hybrid Regulatory Pathways – Recognizing phytochemicals as "botanical drugs" (as in FDA's botanical guidance) to bridge the gap between dietary supplements and pharmaceuticals [161].
- Standardization and Quality Control – Requiring defined levels of active constituents and validated methods for purity testing [162].
- Global Harmonization – Aligning standards across the US, EU, and Asia to facilitate international use [163].

FUTURE ROADMAP: NEXT-GENERATION THERAPEUTICS

The future of phytochemical therapeutics will be shaped by convergence of biotechnology, nanomedicine, AI, and systems biology:

1. Next-Generation Delivery Systems – Smart nanoparticles capable of targeting pancreatic β-cells or liver tissue.
2. Designer Polyphenols – Synthetic modifications of natural scaffolds to enhance potency and stability.
3. Gut Microbiome-Targeted Phytochemicals – Leveraging microbiota modulation as a therapeutic axis.
4. AI-Driven Clinical Trial Design – Using predictive models to optimize patient selection and trial endpoints.
5. Integration into Digital Health – Mobile health platforms monitoring phytochemical use, diet, and glucose levels in real time [163].

REFERENCES

1. American Diabetes Association. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S19–40.
2. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98.

3. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.
4. Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019;62(1):3–16.
5. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–85.
6. Nauck MA, Meier JJ. Management of endocrine disease: Are all GLP-1 agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol. 2019;181(6):R211–34.
7. Garber AJ. Long-term safety of oral antidiabetic drugs. Drugs. 2010;70(6):725–40.
8. Neumiller JJ, White JR, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs. 2010;70(4):377–85.
9. Wajchenberg BL. β-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28(2):187–218.
10. Grover JK, Yadav S, Vats V. Medicinal plants of India with anti-diabetic potential. J Ethnopharmacol. 2002;81(1):81–100.
11. Li WL, Zheng HC, Bukuru J, De Kimpe N. Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. J Ethnopharmacol. 2004;92(1):1–21.
12. Joseph B, Jini D. Antidiabetic effects of Momordica charantia (bitter melon) and its medicinal potency. Asian Pac J Trop Dis. 2013;3(2):93–102.
13. Basch E, Ulbricht C, Kuo G, Szapary P, Smith M. Therapeutic applications of fenugreek. Altern Med Rev. 2003;8(1):20–7.
14. Tiwari P, Mishra BN, Sangwan NS. Phytochemical and pharmacological properties of Gymnema sylvestre: an important medicinal plant. Biomed Res Int. 2014;2014:830285.
15. Jung UJ, Lee MK, Park YB, Kang MA, Choi MS. Effect of citrus flavonoids on lipid metabolism and glucose-regulating enzyme mRNA levels in type-2 diabetic mice. Int J Biochem Cell Biol. 2006;38(7):1134–45.
16. Patel DK, Prasad SK, Kumar R, Hemalatha S. An overview on antidiabetic medicinal plants having insulin mimetic property. Asian Pac J Trop Biomed. 2012;2(4):320–30.
17. Liu Q, Zhu R, Meng X, Sun A, Zhu Y, Liu X. Antidiabetic effects and mechanisms of dietary flavonoids: a comprehensive review. Crit Rev Food Sci Nutr. 2021;61(2):1–20.
18. Williamson EM. Synergy and other interactions in phytomedicines. Phytomedicine. 2001;8(5):401–9.
19. Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, Linder T, Wawrosch C, Uhrin P, et al. Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol Adv. 2015;33(8):1582–614.
20. Tang W, Eisenbrand G. Chinese drugs of plant origin: chemistry, pharmacology, and use in traditional and modern medicine. Berlin: Springer-Verlag; 1992.
21. Kulkarni SK, Dhir A. Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders. Phytother Res. 2010;24(3):317–24.
22. Meng X, Wang M, Sun G, Ye J, Xu H, Wang H. Role of resveratrol in regulation of glucose homeostasis and insulin sensitivity: a review. Crit Rev Food Sci Nutr. 2020;60(1):1–14.
23. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013;15(1):195–218.
24. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712–7.
25. Li Y, Wang X, Chen T, Wang C, Yang Z, Wang Y. Nanotechnology-based drug delivery systems for enhanced bioactivity of phytochemicals. J Drug Deliv Sci Technol. 2021;63:102540.
26. Zhang R, Zhu X, Bai H, Ning K. Network pharmacology databases for traditional Chinese medicine: review and assessment. Front Pharmacol. 2019;10:123.
27. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014;4:177.
28. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014;4:177.

29. Li WL, Zheng HC, Bukuru J, De Kimpe N. Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. J Ethnopharmacol. 2004;92(1):1–21.
30. Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, Linder T, Wawrosch C, Uhrin P, et al. Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol Adv. 2015;33(8):1582–614.
31. Tang W, Eisenbrand G. Chinese drugs of plant origin: chemistry, pharmacology, and use in traditional and modern medicine. Berlin: Springer-Verlag; 1992.
32. Patel DK, Prasad SK, Kumar R, Hemalatha S. An overview on antidiabetic medicinal plants having insulin mimetic property. Asian Pac J Trop Biomed. 2012;2(4):320–30.
33. Kulkarni SK, Dhir A. Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders. Phytother Res. 2010;24(3):317–24.
34. Kumar A, Ekavali, Chopra K, Mukherjee M, Pottabathini R, Dhull DK. Current knowledge and pharmacological profile of berberine: an update. Eur J Pharmacol. 2015;761:288–97.
35. Liu Q, Zhu R, Meng X, Sun A, Zhu Y, Liu X. Antidiabetic effects and mechanisms of dietary flavonoids: a comprehensive review. Crit Rev Food Sci Nutr. 2021;61(2):1–20.
36. Attele AS, Zhou YP, Xie JT, Wu JA, Zhang L, Dey L, et al. Antidiabetic effects of Panax ginseng berry extract and the identification of an effective component. Diabetes. 2002;51(6):1851–8.
37. Ong KW, Hsu A, Tan BK. Chlorogenic acid stimulates glucose transport in skeletal muscle via AMPK activation: a contributor to the beneficial effects of coffee on diabetes. PLoS One. 2012;7(3):e32718.
38. Sharma BR, Rhyu DY. Anti-diabetic effects of saponins from Pueraria lobata root in type 2 diabetic mice fed with high-fat diet. Food Chem Toxicol. 2014;69:244–50.
39. Meng X, Wang M, Sun G, Ye J, Xu H, Wang H. Role of resveratrol in regulation of glucose homeostasis and insulin sensitivity: a review. Crit Rev Food Sci Nutr. 2020;60(1):1–14.
40. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013;15(1):195–218.
41. Joseph B, Jini D. Antidiabetic effects of Momordica charantia (bitter melon) and its medicinal potency. Asian Pac J Trop Dis. 2013;3(2):93–102.
42. Tiwari P, Mishra BN, Sangwan NS. Phytochemical and pharmacological properties of Gymnema sylvestre: an important medicinal plant. Biomed Res Int. 2014;2014:830285.
43. Jung UJ, Lee MK, Park YB, Kang MA, Choi MS. Effect of citrus flavonoids on lipid metabolism and glucose-regulating enzyme mRNA levels in type-2 diabetic mice. Int J Biochem Cell Biol. 2006;38(7):1134–45.
44. Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016;164(11):740–51.
45. Xie JT, Mehendale SR, Li X, Quigg R, Wang X, Wang CZ, et al. Anti-diabetic effect of ginsenoside Re in ob/ob mice. Biochim Biophys Acta. 2005;1740(3):319–25.
46. Liu D, Zhen W, Yang Z, Carter JD, Si H, Reynolds KA. Genistein acutely stimulates insulin secretion in pancreatic β-cells through a cAMP-dependent protein kinase pathway. Diabetes. 2006;55(4):1043–50.
47. Williamson EM. Synergy and other interactions in phytomedicines. Phytomedicine. 2001;8(5):401–9.
48. Xu J, Chen HB, Li SL. Understanding the molecular mechanisms of the interplay between herbal medicines and gut microbiota. Med Res Rev. 2017;37(5):1140–85.
49. Hou SZ, Chen SX, Huang S, Jiang DX, Zhou CJ, Chen CQ, et al. The hypoglycemic effect of berberine and its correlation with the improvement of oxidative stress in streptozotocin-induced diabetic rats. Int J Clin Exp Med. 2011;4(4):270–81.
50. Williamson EM. Synergy in herbal medicines. In: Krämer U, editor. Phytotherapy research developments. Oxford: Wiley; 2015. p. 67–85.
51. Choudhury H, Pandey M, Hua CK, Mun CS, Jing JK, Kong L, et al. An update on natural compounds in the remedy of diabetes mellitus: a systematic review. J Tradit Complement Med. 2018;8(3):361–76.
52. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712–7.

53. Bhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res. 2012;32(7):537–41.
54. Panahi Y, Hosseini MS, Khalili N, Naimi E, Simental-Mendía LE, Majeed M, et al. Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: a post-hoc analysis of a randomized controlled trial. Biomed Pharmacother. 2016;82:578–82.
55. Ekor M. Herbal medicines: safety issues and regulatory challenges. In: Benzie IFF, Wachtel-Galor S, editors. Herbal Medicine: Biomolecular and Clinical Aspects. 2nd ed. Boca Raton: CRC Press; 2011. p. 323–38.
56. Posadzki P, Watson LK, Ernst E. Herb-drug interactions: an overview of systematic reviews. Br J Clin Pharmacol. 2013;75(3):603–18.
57. Bhattacharya S. Natural antidiabetic phytochemicals: molecular targets and mechanisms. Front Endocrinol. 2018;9:451.
58. Zhou L, Wang X, Shao L, Yang Y, Shang W, Yuan G, et al. Berberine acutely inhibits insulin secretion from β-cells through 3′,5′-cyclic adenosine monophosphate signaling. Endocrinology. 2008;149(9):4514–23.
59. Gupta A, Gupta R, Lal B. Effect of Trigonella foenum-graecum seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: a double blind placebo controlled study. J Assoc Physicians India. 2001;49:1057–61.
60. Jayaprakasam B, Vareed SK, Olson LK, Nair MG. Insulin secretion by bioactive anthocyanins and anthocyanidins present in fruits. J Agric Food Chem. 2005;53(1):28–31.
61. Liu D, Zhen W, Yang Z, Carter JD, Si H, Reynolds KA. Genistein acutely stimulates insulin secretion in pancreatic β-cells through a cAMP-dependent protein kinase pathway. Diabetes. 2006;55(4):1043–50.
62. Xie JT, Mehendale SR, Li X, Quigg R, Wang X, Wang CZ, et al. Anti-diabetic effect of ginsenoside Re in ob/ob mice. Biochim Biophys Acta. 2005;1740(3):319–25.
63. Watanabe J, Kawabata J, Kurihara H, Niki R. Isolation and identification of α-glucosidase inhibitors from Tochu-cha (Eucommia ulmoides). Biosci Biotechnol Biochem. 1997;61(1):177–8.
64. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493–506.
65. Sharma BR, Rhyu DY. Anti-diabetic effects of diosgenin in diabetic animal models. Biomed Pharmacother. 2017;95:524–9.
66. Weisberg SP, Leibel R, Tortoriello DV. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of metabolic syndrome. Endocrinology. 2008;149(7):3549–58.
67. Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, et al. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor–deficient mice. Diabetes. 2006;55(8):2180–91.
68. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARγ. Annu Rev Biochem. 2008;77:289–312.
69. Adisakwattana S, Chantarasinlapin P, Thammarat H, Yibchok-anun S. A series of cinnamic acid derivatives and their inhibitory activity on intestinal α-glucosidase. J Enzyme Inhib Med Chem. 2009;24(5):1194–200.
70. Hanhineva K, Törrönen R, Bondia-Pons I, Pekkinen J, Kolehmainen M, Mykkänen H, et al. Impact of dietary polyphenols on carbohydrate metabolism. Int J Mol Sci. 2010;11(4):1365–402.
71. Tadera K, Minami Y, Takamatsu K, Matsuoka T. Inhibition of α-glucosidase and α-amylase by flavonoids. J Nutr Sci Vitaminol. 2006;52(2):149–53.
72. Van de Laar FA. Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes. Vasc Health Risk Manag. 2008;4(6):1189–95.
73. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol. 2009;41(1):40–59.
74. Calabrese V, Cornelius C, Dinkova-Kostova AT, Iavicoli I, Di Paola R, Koverech A, et al. Cellular stress responses, hormetic phytochemicals and vitagenes in aging and longevity. Biochim Biophys Acta. 2012;1822(5):753–83.

75. Kowluru RA, Kanwar M. Oxidative stress and the development of diabetic retinopathy: contributory role of matrix metalloproteinase-2. Free Radic Biol Med. 2009;46(12):1677–85.
76. Brasnyó P, Molnár GA, Mohás M, Markó L, Laczy B, Cseh J, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 2011;106(3):383–9.
77. Panahi Y, Khalili N, Sahebi E, Namazi S, Reiner Ž, Majeed M, et al. Curcuminoids modify lipid profile in type 2 diabetes mellitus: a randomized controlled trial. Phytother Res. 2014;28(4):514–8.
78. Aggarwal BB, Gupta SC, Sung B. Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol. 2013;169(8):1672–92.
79. Rivera L, Morón R, Sánchez M, Zarzuelo A, Galisteo M. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity. 2008;16(9):2081–7.
80. Cho WC, Chung WS, Lee SK, Leung AW, Cheng CH, Yue KK. Ginsenoside Re of Panax ginseng possesses significant antioxidant and antihyperlipidemic effects in streptozotocin-induced diabetic rats. Eur J Pharmacol. 2006;550(1–3):173–9.
81. Cardona F, Andrés-Lacueva C, Tulipani S, Tinahones FJ, Queipo-Ortuño MI. Benefits of polyphenols on gut microbiota and implications in human health. J Nutr Biochem. 2013;24(8):1415–22.
82. Zhang X, Zhao Y, Zhang M, Pang X, Xu J, Kang C, et al. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One. 2012;7(8):e42529.
83. Selma MV, Espín JC, Tomás-Barberán FA. Interaction between phenolics and gut microbiota: role in human health. J Agric Food Chem. 2009;57(15):6485–501.
84. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334(6052):105–8.
85. Rahbar S, Figarola JL. Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys. 2003;419(1):63–79.
86. Cai W, He JC, Zhu L, Chen X, Zheng F, Striker GE, et al. Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci USA. 2006;103(37):13801–6.
87. Yu W, Cao Q, Chen L, Feng R, Chen H, Wang H, et al. Curcumin exerts hypoglycemic effect via PPARγ activation in HepG2 cells. Chem Biol Interact. 2018;286:33–40.
88. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell. 2006;127(6):1109–22.
89. Zhang J, Chen L, Zheng J, Zeng T, Li H, Wang J, et al. Quercetin affects the expression of microRNAs involved in lipid metabolism and inflammation in high-fat diet mice. Int J Mol Sci. 2019;20(5):1239.
90. Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008;93(7):2559–65.
91. Turner N, Li JY, Gosby A, To SW, Cheng Z, Miyoshi H, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMPK and improve insulin action. Diabetes. 2008;57(5):1414–8.
92. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006;55(8):2256–64.
93. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712–7.
94. Liu YT, Hao HP, Xie HG, Lai L, Wang Q, Liu CX, et al. Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug Metab Dispos. 2010;38(10):1779–84.
95. Hua W, Ding L, Chen Y, Gong B, He J, Xu G, et al. Determination of berberine in human plasma by liquid chromatography–electrospray ionization–mass spectrometry. J Pharm Biomed Anal. 2007;44(4):931–7.

96. Weisberg SP, Leibel R, Tortoriello DV. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of metabolic syndrome. Endocrinology. 2008;149(7):3549–58.
97. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. Curcumin extract for prevention of type 2 diabetes. Diabetes Care. 2012;35(11):2121–7.
98. Panahi Y, Khalili N, Sahebi E, Namazi S, Reiner Ž, Majeed M, et al. Curcuminoids modify lipid profile in type 2 diabetes mellitus: a randomized controlled trial. Phytother Res. 2014;28(4):514–8.
99. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353–6.
100. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493–506.
101. Qiao Y, Sun J, Xia S, Tang X, Shi Y, Le G. Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fat diet–induced obesity. Food Funct. 2014;5(6):1241–9.
102. Brasnyó P, Molnár GA, Mohás M, Markó L, Laczy B, Cseh J, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 2011;106(3):383–9.
103. Hausenblas HA, Schoulda JA, Smoliga JM. Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus: systematic review and meta-analysis. Mol Nutr Food Res. 2015;59(1):147–59.
104. Walle T. Bioavailability of resveratrol. Ann N Y Acad Sci. 2011;1215:9–15.
105. Jung UJ, Lee MK, Park YB, Kang MA, Choi MS. Effect of citrus flavonoids on lipid metabolism and glucose-regulating enzyme mRNA levels in type-2 diabetic mice. Int J Biochem Cell Biol. 2006;38(7):1134–45.
106. Boots AW, Haenen GR, Bast A. Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol. 2008;585(2–3):325–37.
107. Egert S, Bosy-Westphal A, Seiberl J, Kürbitz C, Settler U, Plachta-Danielzik S, et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. Br J Nutr. 2009;102(7):1065–74.
108. Li Y, Yao J, Han C, Yang J, Chaudhry MT, Wang S, et al. Quercetin, inflammation and immunity. Nutrients. 2016;8(3):167.
109. Attele AS, Zhou YP, Xie JT, Wu JA, Zhang L, Dey L, et al. Antidiabetic effects of Panax ginseng berry extract and the identification of an effective component. Diabetes. 2002;51(6):1851–8.
110. Cho WC, Chung WS, Lee SK, Leung AW, Cheng CH, Yue KK. Ginsenoside Re of Panax ginseng possesses significant antioxidant and antihyperlipidemic effects in streptozotocin-induced diabetic rats. Eur J Pharmacol. 2006;550(1–3):173–9.
111. Vuksan V, Sievenpiper JL, Koo VY, Francis T, Beljan-Zdravkovic U, Xu Z, et al. American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. Arch Intern Med. 2000;160(7):1009–13.
112. Yuan HD, Kim JT, Kim SH, Chung SH. Ginseng and diabetes: the evidences from in vitro, animal and human studies. J Ginseng Res. 2012;36(1):27–39.
113. Sellamuthu PS, Arulselvan P, Kamalraj S, Fakurazi S, Kandasamy M, Arumugam S. Protective nature of mangiferin on oxidative stress and antioxidant status in tissues of streptozotocin-induced diabetic rats. ISRN Pharmacol. 2013;2013:750109.
114. Muruganandan S, Gupta S, Kataria M, Lal J, Gupta PK. Mangiferin protects the streptozotocin-induced oxidative damage and β-cell dysfunction in rat pancreas. Phytother Res. 2005;19(9):725–30.
115. Patel DK, Kumar R, Prasad SK, Sairam K, Hemalatha S. Antidiabetic and in vitro antioxidant potential of Hybanthus enneaspermus (Linn.) F. Muell in streptozotocin-induced diabetic rats. Asian Pac J Trop Biomed. 2011;1(4):316–22.
116. Wolfram S. Effects of green tea and EGCG on cardiovascular and metabolic health. J Am Coll Nutr. 2007;26(4):373S–88S.
117. Van Dijk AE, Olthof MR, Meeuse JC, Seebus E, Heine RJ, van Dam RM. Acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on glucose tolerance. Diabetes Care. 2009;32(6):1023–5.

118. Tiwari P, Mishra BN, Sangwan NS. Phytochemical and pharmacological properties of Gymnema sylvestre: an important medicinal plant. Biomed Res Int. 2014;2014:830285.
119. Gurley BJ, Fifer EK, Gardner Z. Pharmacokinetic herb–drug interactions: clinical evidence and regulatory implications. Planta Med. 2012;78(13):1401–15.
120. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and regulatory challenges. Front Pharmacol. 2014;4:177.
121. Chen C, Zhang Y, Huang C. Berberine in diabetes and its therapeutic potential. Evid Based Complement Alternat Med. 2011;2011: 571281.
122. Guo Y, Li J, Li Y, Xu Y, Xu Y. Pharmacokinetic interactions between berberine and drugs metabolized by CYP enzymes. Eur J Drug Metab Pharmacokinet. 2012;37(3):129–36.
123. Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, et al. Dose escalation of curcumin in humans: safety assessment. Cancer Epidemiol Biomarkers Prev. 2006;15(12):261–9.
124. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–18.
125. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, et al. Repeat dose study of resveratrol in humans. Cancer Res. 2010;70(19):9003–11.
126. Zordoky BN, Robertson IM, Dyck JR. Resveratrol and cardiovascular health: facts and controversies. Clin Sci (Lond). 2015;129(8):701–20.
127. Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC. A critical review of quercetin and its safety profile. Food Chem Toxicol. 2007;45(11):2179–205.
128. Andres S, Pevny S, Ziegenhagen R, Bakhiya N, Schäfer B, Hirsch-Ernst KI, et al. Safety aspects of the use of quercetin as a dietary supplement. Mol Nutr Food Res. 2018;62(1):1700447.
129. Vuksan V, Sievenpiper JL, Koo VY, Francis T, Beljan-Zdravkovic U, Xu Z, et al. American ginseng improves glycemia in T2DM. Diabetes Care. 2000;23(9):1221–6.
130. Yuan CS, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S, et al. Ginseng and hypoglycemia: case report and review. J Clin Pharmacol. 2004;44(6):690–3.
131. Williamson EM. Interactions between herbal and conventional medicines: overview of the mechanisms. Drugs. 2003;63(14):1549–61.
132. Sharma V, Sharma C, Paliwal R. Toxicological considerations in phytomedicine. J Biol Active Prod Nat. 2014;4(5):320–35.
133. Meng F, Henson R, Wehbe-Janek H, Smith H, Ueno Y, Patel T. Berberine induces hepatotoxicity at high doses in mice. Toxicol Appl Pharmacol. 2007;223(2):177–83.
134. Boots AW, Haenen GR, Bast A. Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol. 2008;585(2–3):325–37.
135. Johnson WD, Morrissey RL, Usborne AL, Kapetanovic IM, Crowell JA, Muzzio M, et al. Subchronic toxicity of resveratrol. Toxicol Sci. 2011;119(1):187–97.
136. U.S. FDA. Dietary Supplement Health and Education Act of 1994 (DSHEA). U.S. Food & Drug Administration.
137. European Medicines Agency. Directive 2004/24/EC – Traditional Herbal Medicinal Products. EMA, 2004.
138. Patwardhan B, Warude D, Pushpangadan P, Bhatt N. Ayurveda and traditional medicine: a review. World Health Forum. 2005;26(4):318–27.
139. Posadzki P, Watson LK, Ernst E. Adverse effects of herbal medicines: overview of systematic reviews. Clin Med (Lond). 2013;13(1):7–12.
140. Barnes J. Quality, efficacy and safety of complementary medicines: fashions, facts and the future. Part II: Efficacy and safety. Br J Clin Pharmacol. 2003;55(4):331–40.
141. Sreekanth CN, Bhatnagar R, Pandey A. Nanotechnology-based approaches for phytochemical delivery in diabetes. Curr Drug Metab. 2019;20(9):706–18.
142. Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: a future nanomedicine for cancer. Drug Discov Today. 2012;17(1–2):71–80.
143. Chen Y, Li M, Xing Z, Wang S, Liu Z, Ma J. Artificial intelligence-assisted prediction of herb–drug interactions. Front Pharmacol. 2021;12:730865
144. Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov. 2021;20(3):200–16.

145. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–18.
146. Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanoformulations: a future nanomedicine. Drug Discov Today. 2012;17(1–2):71–80.
147. Kidd PM. Bioavailability and activity of phytosome complexes from botanical polyphenols. Altern Med Rev. 2009;14(3):226–46.
148. Chen L, Wang Y, Wang J. Prodrug strategies for improving phytochemical bioavailability. Curr Pharm Des. 2018;24(22):2579–89.
149. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on curcumin pharmacokinetics. Planta Med. 1998;64(4):353–6.
150. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682–90.
151. Qiao Y, Sun J, Xia S, Tang X, Shi Y, Le G. Resveratrol and gut microbiota modulation. Food Funct. 2014;5(6):1241–9.
152. Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med. 2013;11(2):110–20.
153. Chen Y, Li M, Xing Z, Wang S, Liu Z, Ma J. Artificial intelligence-assisted prediction of phytochemical activities. Front Pharmacol. 2021;12:730865.
154. Ordovas JM, Ferguson LR, Tai ES, Mathers JC. Personalised nutrition and health. BMJ. 2018;361:k2173.
155. Zhang X, Zhao Y, Xu J, Xue Z, Zhang M, Pang X, et al. Modulation of gut microbiota by berberine. Nat Commun. 2015;6:8028.
156. Egert S, Bosy-Westphal A, Seiberl J, Kürbitz C, Settler U, Plachta-Danielzik S, et al. Quercetin reduces systolic blood pressure in overweight subjects. Br J Nutr. 2009;102(7):1065–74.
157. Williamson EM. Synergy and other interactions in phytomedicines. Phytomedicine. 2001;8(5):401–9.
158. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712–7.
159. Kennedy DO, Wightman EL, Reay JL, Lietz G, Okello EJ, Wilde A, et al. Effects of Panax ginseng, ginkgo biloba and quercetin. Psychopharmacology. 2008;197(3):465–73.
160. U.S. FDA. Botanical Drug Development Guidance for Industry. U.S. Food & Drug Administration. 2016.
161. Barnes J. Quality, efficacy and safety of complementary medicines. Br J Clin Pharmacol. 2003;55(4):331–40.
162. Posadzki P, Watson LK, Ernst E. Adverse effects of herbal medicines. Clin Med (Lond). 2013;13(1):7–12.
163. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–56.